|Series A, 7/2010 |
Vectis Healthcare & Life Sciences Fund
|Venture Round, 12/2011 ||$5.55M|
|Partial Close, 1/2013 ||$9.13M|
|Series D, 6/2013 |
Vectis Healthcare & Life Sciences Fund II
EndoStim is a St. Louis start-up that makes medical devices to treat gastrointestinal and urological neuro-muscular disorders. EndoStim is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Drugs known as proton pump inhibitors (PPIs) are the standard of care for GERD treatment but they do not address the root-cause of GERD. In severe cases, patients may opt for surgical anti-reflux procedures that are costly and invasive. EndoStim has developed a procedure that offers a lower cost, interventional solution for treating severe or refractory GERD and reach the many patients currently unresponsive to or dissatisfied with their medical therapy. GERD affects hundreds of millions of patients worldwide, including 30 million in the United States.